Methods and reagents for the detection of melanoma
First Claim
Patent Images
1. A method of identifying a melanoma comprising the steps of a. obtaining a tissue sample;
- and b. measuring the expression levels in the sample of genes encoding mRNA corresponding to PLAB (SEQ ID NO;
1) and LlCAM (SEQ ID NO;
2);
or PLAB, LlCAM and NTRK3 (SEQ ID NO;
3) wherein the gene expression levels above pre-determined cut-off levels are indicative of the presence of a melanoma in the sample.
1 Assignment
0 Petitions
Accused Products
Abstract
An assay for identifying a malignant melanocyte is conducted by determining whether differential expression of particular genes is indicative of melanoma exceed a cut-off value. The assay can be performed intra-operatively on lymph node tissue.
-
Citations
221 Claims
-
1. A method of identifying a melanoma comprising the steps of
a. obtaining a tissue sample; - and
b. measuring the expression levels in the sample of genes encoding mRNA corresponding to PLAB (SEQ ID NO;
1) and LlCAM (SEQ ID NO;
2);
orPLAB, LlCAM and NTRK3 (SEQ ID NO;
3)wherein the gene expression levels above pre-determined cut-off levels are indicative of the presence of a melanoma in the sample. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)
- and
-
37. A method of identifying a melanoma comprising the steps of
a. obtaining a tissue sample; - and
b. measuring the expression levels in the sample of genes encoding niRNA recognized by the primer/probe sets selected from the group consisting of SEQ ID NOs;
4-6 or SEQ ID NOs;
7-9 and SEQ ID NOs;
10-12 or SEQ ID NOs;
13-15;
orSEQ ID NOs;
4-6 or SEQ ID NOs;
7-9 and SEQ ID NOs;
10-12 or SEQ ID NOs;
13-15 and SEQ ID NOs;
16-18wherein the gene expression levels above pre-determined cut-off levels are indicative of the presence of a melanoma in the sample. - View Dependent Claims (38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)
- and
-
73. A method of distinguishing a malignant melanocyte from a benign melanocyte comprising the steps of
a. obtaining a tissue sample; - and
b. measuring the expression levels in the sample of genes encoding PLAB (SEQ ID NO;
1) and LlCAM (SEQ ID NO;
2);
orPLAB, LlCAM and NTRK3 (SEQ ID NO;
3)wherein the gene expression levels above pre-determined cut-off levels are indicative of the presence of a malignant melanocyte in the sample. - View Dependent Claims (74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108)
- and
-
109. A method of distinguishing a malignant melanocyte from a benign melanocyte comprising the steps of
a. obtaining a tissue sample; - and
b. measuring the expression levels in the sample of genes recognized by the primer/probe sets selected from the group consisting of SEQ ID NOs;
4-6 or SEQ ID NOs;
7-9 and SEQ ID NOs;
10-12 or SEQ ID NOs;
13-15;
orSEQ ID NOs;
4-6 or SEQ ID NOs;
7-9 and SEQ ID NOs;
10-12 or SEQ ID NOs;
13-15 and SEQ ID NOs;
16-18wherein the gene expression levels above pre-determined cut-off levels are indicative of the presence of a malignant melanocyte in the sample. - View Dependent Claims (110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144)
- and
-
145. A method of determining patient treatment protocol comprising the steps of
a. obtaining a tissue sample from the patient; - and
b. measuring the expression levels in the sample of genes encoding PLAB (SEQ ID NO;
1) and LlCAM (SEQ ID NO;
2);
orPLAB, LlCAM and NTRK3 (SEQ ID NO;
3)wherein the gene expression levels above pre-determined cut-off levels are indicative of the presence of a melanoma in the sample. - View Dependent Claims (146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180)
- and
-
181. A method of determining patient treatment protocol comprising the steps of
a. obtaining a tissue sample from the patient; - and
b. measuring the expression levels in the sample of genes identified by the primer/probe sets selected from the group consisting of SEQ ID NOs;
4-6 or SEQ ID NOs;
7-9 and SEQ ID NOs;
10-12 or SEQ ID NOs;
13-15;
orSEQ ID NOs;
4-6 or SEQ ID NOs;
7-9 and SEQ ID NOs;
10-12 or SEQ ID NOs;
13-15 and SEQ ID NOs;
16-18wherein the gene expression levels above pre-determined cut-off levels are indicative of the presence of a melanoma in the sample. - View Dependent Claims (182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216)
- and
-
217. A composition comprising at least one primer/probe set selected from the group consisting of:
- SEQ ID NOs;
4-6, SEQ ID NOs;
7-9, SEQ ID NO;
46-48, SEQ ID NOs;
13-15, SEQ ID NOs;
16-18, SEQ ID NOs;
19-21, and SEQ ID NOs;
22-24.
- SEQ ID NOs;
-
218. A composition comprising at least one amplicon selected from the group consisting of SEQ ID NOs:
- 25-28.
-
219. A kit for conducting an assay to determine the presence of melanoma in a tissue sample comprising:
- nucleic acid amplification and detection reagents.
- View Dependent Claims (220, 221)
Specification